Press Releases

Date Title View
Toggle Summary Second Sight Medical Products, Inc. to Present at the Inaugural LD Micro Virtual Investor Conference on March 7, 2018
SYLMAR, Calif. --(BUSINESS WIRE)--Mar. 5, 2018-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today
View HTML
Toggle Summary Second Sight to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018 Conference Call
SYLMAR, Calif. --(BUSINESS WIRE)--Feb. 28, 2018-- Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind patients, will release its fourth quarter and
View HTML
Toggle Summary Second Sight Announces Market Entry into Singapore with First Implant of Argus II Retinal Prosthesis System
SYLMAR, Calif. --(BUSINESS WIRE)--Feb. 16, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind patients, today
View HTML
Toggle Summary Second Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant
SYLMAR, Calif. --(BUSINESS WIRE)--Feb. 5, 2018-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today
View HTML
Toggle Summary Second Sight Announces Market Entry into Iran with First Two Implants of Argus II Retinal Prosthesis System
- Marks Continued Global Expansion of Argus II for Individuals Blinded by Retinitis Pigmentosa - SYLMAR, Calif. --(BUSINESS WIRE)--Dec. 5, 2017-- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual
View HTML
Toggle Summary Ontario Health Technology Advisory Committee Recommends Public Funding for Second Sight’s Argus II Retinal Prosthesis System
SYLMAR, Calif. --(BUSINESS WIRE)--Nov. 10, 2017-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today
View HTML
Toggle Summary Second Sight Receives FDA Expedited Access Pathway Designation for the Orion Cortical Visual Prosthesis System
-- Allows patients to have more timely access to medical devices by expediting their development, assessment, and review -- SYLMAR, Calif. --(BUSINESS WIRE)--Nov. 8, 2017-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of
View HTML
Toggle Summary Second Sight Reports Third Quarter 2017 Financial Results
SYLMAR, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today
View HTML
Toggle Summary Second Sight Receives Full FDA Approval to Begin First Orion Human Clinical Study
--Second Sight has completed additional device testing and addressed outstanding questions previously requested by the FDA -- SYLMAR, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer
View HTML
Toggle Summary Second Sight Announces Final Medicare Hospital Outpatient Payment Rate for 2018 for the Argus II Retinal Prosthesis System
SYLMAR, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Second Sight Medical Products , Inc. (NASDAQ:EYES) ("Second Sight"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the
View HTML